Olympus Corp. (7733)

Currency in JPY
1,614.0
-238.5(-12.87%)
Closed·
Unusual trading volume
7733 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1,603.01,667.5
52 wk Range
1,443.02,168.0
Key Statistics
Bid/Ask
1,613.50 / 1,614.50
Prev. Close
1,852.5
Open
1,667.5
Day's Range
1,603-1,667.5
52 wk Range
1,443-2,168
Volume
12.72M
Average Volume (3m)
3.25M
1-Year Change
-29.0549%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
7733 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2,050.0
Upside
+27.01%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 6 consecutive years

Olympus Corp. News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Olympus Corp. Company Profile

Olympus Corporation, together with its subsidiaries, manufactures and sells medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through Endoscopic Solutions Business, Therapeutic Solutions Business, and Other segments. The company offers gastrointestinal endoscopy system products comprising video endoscopy and ultrasound systems; GI endotherapy products consisting of CRC devices and HPB devices/hemostasis products; endoscopic solutions ecosystem products, including intelligent ecosystem operating software platforms, and AI insights and computer-aided detection/diagnosis products; reprocessing products, such as endoscope reprocessors, chemicals, accessories, and peripherals; and medical services, which include repair center services. It also provides respiratory products comprising bronchoscopy systems and devices, lung cancer products, and chronic obstructive pulmonary disease products; urology products consisting of visualization, stone management, benign prostatic hyperplasia (BPH), and BPH + bladder cancer products; surgical products, such as surgical endoscopy systems, advanced energy devices, surgical microscope, integrated procedure room solutions, and rhino-laryngoscopy systems, as well as surgical devices for the ears, nose, and throat; and gastroenterology devices and gynecology products. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was incorporated in 1919 and is headquartered in Hachioji, Japan.

Employees
29297
Market
Japan

Olympus Corp. Earnings Call Summary for Q3/2026

  • Olympus Corp. revised Q3 2025 revenue guidance down 2%, causing stock to fall 5.22% to 1954.5 yen amid U.S. market challenges.
  • The company targets margin expansion of 100+ basis points from FY 2027 and has increased structural cost reduction to JPY 31 billion.
  • Despite reduced gross margins due to ship holds and inventory actions, Olympus forecasts a return to growth in Q4 with mid-single-digit revenue targets.
  • CEO Bob emphasized leadership transformation and maintained the company's commitment to 20%+ operating margin goals despite current challenges.
  • New product launches in the GI segment are planned as part of the company's strategy to overcome supply chain issues and competitive pressures.
Last Updated: 02/14/2026, 02:14 AM
Read Full Transcript

Compare 7733 to Peers and Sector

Metrics to compare
7733
Peers
Sector
Relationship
P/E Ratio
24.1x22.0x−0.5x
PEG Ratio
4.550.640.00
Price/Book
2.6x1.9x2.6x
Price / LTM Sales
2.1x1.6x3.3x
Upside (Analyst Target)
23.9%23.1%47.0%
Fair Value Upside
Unlock16.3%5.9%Unlock

Analyst Ratings

4 Buy
9 Hold
1 Sell
Ratings:
14 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 2,050.0
(+27.01% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Morgan Stanley
Hold2,300.00+42.50%2,700.00DowngradeJan 21, 2026
Nomura/Instinet
Hold1,900.00+17.72%1,800.00MaintainNov 25, 2025
Citi
Buy2,300.00+42.50%2,500.00MaintainOct 22, 2025
Macquarie
Hold2,000.00+23.92%-MaintainOct 14, 2025
JPMorgan
Buy2,100.00+30.11%2,350.00MaintainOct 02, 2025

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 75.67%
Dividend Yield
1.86%
Industry Median 1.56%
Annualized payout
30.00
Paid unevenly
5-Years Growth
+14.87%
Growth Streak

Earnings

Latest Release
Feb 13, 2026
EPS / Forecast
12.87 / 22.56
Revenue / Forecast
261.05B / 259.88B
EPS Revisions
Last 90 days

7733 Income Statement

People Also Watch

5,086.0
6501
-2.36%
4,200.0
6701
+2.46%
3,543.0
1605
+2.02%
5,990.0
2914
-1.59%

FAQ

What Is the Olympus Corp. (7733) Stock Price Today?

The Olympus Corp. stock price today is 1,614.0

What Stock Exchange Does Olympus Corp. Trade On?

Olympus Corp. is listed and trades on the Tokyo Stock Exchange.

What Is the Stock Symbol for Olympus Corp.?

The stock symbol for Olympus Corp. is "7733."

Does Olympus Corp. Pay Dividends? What’s The Current Dividend Yield?

The Olympus Corp. dividend yield is 1.86%.

What Is the Olympus Corp. Market Cap?

As of today, Olympus Corp. market cap is 1.78T.

What Is Olympus Corp.'s Earnings Per Share (TTM)?

The Olympus Corp. EPS (TTM) is 75.7.

When Is the Next Olympus Corp. Earnings Date?

Olympus Corp. will release its next earnings report on May 08, 2026.

From a Technical Analysis Perspective, Is 7733 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Olympus Corp. Stock Split?

Olympus Corp. has split 1 times.

How Many Employees Does Olympus Corp. Have?

Olympus Corp. has 29297 employees.

What is the current trading status of Olympus Corp. (7733)?

As of Feb 16, 2026, Olympus Corp. (7733) is trading at a price of 1,614.0, with a previous close of 1,852.5. The stock has fluctuated within a day range of 1,603.0 to 1,667.5, while its 52-week range spans from 1,443.0 to 2,168.0.

What Is Olympus Corp. (7733) Price Target According to Analysts?

The average 12-month price target for Olympus Corp. is JPY2,050.0, with a high estimate of JPY2400 and a low estimate of JPY1750. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +27.01% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.